In recent years, the market for resorbable fillers has been steadily expanding. In
France, the European Community’s (EC) seal of approval is sufficient for distribution.
Approval from the AFSSAPS (French Agency for Safety of Health Products), the French
equivalent of the US Food and Drug Administration (FDA), is not required to market
resorbable fillers, because they are considered to be “implantable medical devices”
and not drugs. Macrolane (Q-Med AB, Uppsala, Sweden) is a NASHA (Stabilized Non-Animal
Hyaluronic Acid) gel-based technology and has been available on the French market
since 2007 as a filler that can be used in all areas of the body except the face.
It is highly crosslinked, and this property slows its absorption into the body but
can also leave long-lasting residues. At the end of 2008, Macrolane received EC approval
for use in breast augmentation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Plastic, Reconstructive & Aesthetic SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Discussion: macrolane for breast enhancement: 12-month follow-up.Plast Reconstr Surg. 2011; 127: 861-862
- Macrolane for breast enhancement: 12-month follow-up.Plast Reconstr Surg. 2011; 127: 850-860
- Macrolane injections for breast enhancement in un-diagnosed breast malignancy: a case report.J Plast Reconstr Aesthet Surg. 2011;
Décision de police sanitaire de l’Afssaps: « Portant restriction de la mise sur le marché et de l’utilisation des dispositifs médicaux injectables indiqués dans le comblement et l’augmentation des volumes corporels à visée esthétique »; August 26, 2011.
- Macrolane(®), a too premature indication in breast augmentation. Focusing on current knowledge of the product.Ann Chir Plast Esthet. 2011; 56: 171-179
Article info
Publication history
Published online: October 24, 2011
Identification
Copyright
© 2011 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Inc. All rights reserved.
